Date: 2014-05-21
Type of information: Initiation of preclinical development
phase: 1
Announcement: completion of the study
Company: aTyr Pharma (USA)
Product: Resokine IV
Action
mechanism: Resokine IV is a physiocrine. Among their various homeostatic functions, some physiocrines act as extracellular signaling molecules to orchestrate immuno-homeostasis in response to stress and other physiological changes. Physiocrines comprise naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and restoring pathophysiological states to a healthier state. aTyr is currently focused on Physiocrines that act as endogenous modulators of our immune system. Physiocrines offer the opportunity for modulating biological pathways through newly discovered naturally occurring mechanisms, many of which may provide multiple therapeutic advantages, including improved efficacy and reduced side effect profiles compared to many existing therapeutics.
Disease:
Therapeutic area: Rare diseases
Country: Europe
Trial
details: The Phase 1 study was a double blinded, placebo-controlled, trial demonstrating that Resokine IV was well tolerated and safe at all doses tested. No serious adverse effects were observed. The data from 32 healthy subjects in four dose cohorts supports the basic premise of Resokine IV as an immuno-modulator rather than a classic interleukin or interferon with systemic immuno-stimulating properties upon administration.
Latest
news: * On May 21, 2014, aTyr Pharma, a rare disease therapeutics enterprise, announced completion of Phase 1 for its lead program, Resokine IV. The study, which marked the first ever administration of a Physiocrine to humans, was conducted in healthy male and female subjects in the European Union to assess the safety and tolerability of Resokine IV. aTyr Pharma is developing Resokine IV as a potential therapeutic for rare immune disorders. This study advances a range of therapeutic programs to treat rare immune-imbalanced diseases and develop a rare disease pipeline in immunology.
